Visiopharm · Pathology image analysis software

Author: Visiopharm

  • Corista and Visiopharm Integrate Capabilities to Offer Enhanced Digital Pathology Experience

    The integration of the two platforms provides immediate access to quantitative image analysis from within Corista’s digital pathology workflow suite

    Corista, an integrated pathology solutions leader, is excited to announce our integration with Visiopharm, a global provider of image analysis software. Corista will extend direct access to Visiopharm’s Oncotopix® from within its award-winning DP3® comprehensive workflow suite.

    Corista’s DP3 is the digital pathology platform of choice for major medical organizations seeking to create a seamless pathology workflow that integrates with all major digital systems, including all whole slide scanners (WSI) and major laboratory information systems (LIS). The addition of Visiopharm’s quantitative image analytics for analyzing data and images provides pathologists with powerful tools to improve their workflows.

    The DP3 platform provides pathologists with embedded capabilities for reading cases, presenting tumor boards, collaborating with colleagues, supporting remote location consults, and facilitating a range of research and educational processes. With today’s announcement, Corista and Visiopharm provide additional ease and powerful functionalities for pathologists while archiving the resulting charts and image insights directly within DP3. Physicians can access the Visiopharm algorithms directly from their DP3 Dashboard and no longer need to leave their desks to access a stand-alone terminal to conduct image analytic routines. Pathologists’ access to Visiopharm’s Oncotopix product suite from within DP3 extends the reach of valuable image analytics while reducing the time to perform each routine.

    “Partnering with Visiopharm is an important extension of Corista’s commitment to providing a complete laboratory workflow solution for analytics, streamlining the work environment for pathologists as they continue to deliver the most comprehensive, up to date, and timely patient care,” Corista Founder, President and CEO Elizabeth Wingard said. “This addition to our platform will extend the use of analytics to a wider range of pathologists as they access these capabilities from inside the Corista platform, receiving results from each analysis directly into the case being reviewed.”

    “We are pleased to add Corista to our partner community, strengthening our support for the integration of solutions that create a more streamlined workflow for pathologists,” said Amanda Lowe, Senior Vice President of Visiopharm. “Our joint customers will benefit from a digital pathology experience that will deliver improved efficiency and standardization.”

    The integration between the two platforms has been completed and is available for installation to existing customers.

  • Get the Newest Release of VIS

    It’s now possible for you to download the new 2018.9 version of VIS. It includes major improvements to Viewing, APP Development and handling of Overlays. The new release also allows you to run our two new state of the art products within the field: AI Deep Learning and ​Phenomap. 

    Please note that this release is for Research Use Only. Download VIS 2018.9

    ​​​​​​​​​​​​​​​​​​​​​​​​​​New features include

    New and Improved APP Author Dialogue
    All the menus for the APP Author are now in a one-page view. This makes it easier for you to access relevant features and define image classes directly in the APP Author Window.

    You are guided through the different steps of the APP development workflow with our new Quick Guide Help dialogue.

    Free Rotation of Images
    An enhancement of the software now allows you to rotate images freely – Try it out! 

    Wheel Menu Updates

    Easier access to a range of different overlay drawing tools including additions such as an eraser, arrow etc.Enter your text here …

    Training videos

    Watch training videos explaining all the functionalities of the New Wheel Menu and the APP Author dialogue in our Customer Center. You can find them under Training Videos & Webinars – Getting Started – Upgrade to 2018.9.

  • Visiopharm Granted a Worldwide Patent on Alignment of Virtual Slides

    The ability to align and subsequently analyze digitized serial sections is gaining importance for a number of research and diagnostic applications related to tissue based biomarkers.

    Tumor Cell Detection:

     One popular application is tumor detection using tumor markers such as Cytokeratin, Melan-A, or other immunohistochemical (IHC) tumor markers. Also H&E stained tissue sections can be useful for tumor detection, despite obvious and well known limitations in robustness and dynamic range.

    Tumor Micro Environment:

    In research applications requiring a quantitative description, e.g. tumor micro-environment, it is often important to be able to look at the co-localization of multiple biomarkers. Here, the alignment of serial sections is a highly efficient approach (see example above).

    Visiopharm’s Tissuealign™ module on alignment of any number of whole slide images of serial sections was granted first in Europe, and then subsequently in the United States in 2012.

    Visiopharm’s patented alignment technology VirtualDoubleStaining™ (VDS) consists of two crucial steps: First, an alignment at low magnification that handles rotation, translation, and local deformations in the tissue samples. Then a second step where the alignment at high-magnification is based on the knowledge established in the first step, and then used for aligning local regions at high resolution.

    In practical terms, it will be difficult to implement alignment methods with sufficient computational efficiency, speed, and accuracy for whole slide images, without using this approach, which was also the basis for Visiopharm’s patented algorithm.

    This fast and highly accurate technology is implemented in the Tissuealign™ module. The module can be used for a range of practical applications, and is currently being used in routine diagnostics and by leading biopharmaceutical companies for drug development and biomarker discovery. Examples are Virtual Double Staining for tumor cell detection using IHC or a more rudimentary H&E. It is simple and efficient to implement this useful principle either for full sections, and Visiopharm is the only company who also has an efficient integration of this principle with TMA workflows. Any number of serial sections can be aligned, and subsequently analyzed simultaneously using Visiopharm’s suite of image analysis modules.

    There are a number webinars available on Visiopharm’s YouTube channel on the technology: “VirtualDoubleStainingTM for beginners” and you can also view the title “Virtual Double Staining: A New Approach for Combining Biomarkers in Research.” 

  • Akoya Biosciences as an Authorized Reseller

    Visiopharm Announces Akoya Biosciences as an Authorized Reseller of Oncotopix® Discovery and Biotopix™

    Visiopharm A/S announced today a partnership with Akoya Biosciences, the technology leader in multiplexed immunofluorescence including the Phenoptics™ portfolio with the Vectra® and Vectra Polaris® systems. As part of this agreement, Akoya becomes an authorized reseller of Visiopharm’s suite of image analysis software, including Phenomap™ and the teach-by-example Artificial Intelligence (AI) modules.

    “Visiopharm is very pleased to have Akoya Biosciences join our partner and authorized reseller community. Our complementary technologies enable scientists and pathologists to better interrogate the disease biology through biomarker discovery and automated cell phenotyping within tissue samples. Our joint customers will benefit from two companies who are committed to driving innovation and providing solutions that deliver efficiency, standardization, and the reproducibility required to support large scale translational studies from discovery through clinical research” said Amanda Lowe, Senior Vice President of Visiopharm.

    Akoya recently announced the acquisition of the Phenoptics portfolio from PerkinElmer, Inc., to complement the CODEX® platform for ultra-high multiplex capabilities. The enables analysis of multiplexed image data from the Mantra®, Vectra and Vectra Polaris platforms with future development for the CODEX technology.

    “Akoya’s focus is to provide customers with end-to-end solutions for high parameter tissue analysis that includes multispectral imaging instruments, reagents, and powerful software.” said Terry Lo, President at Akoya Biosciences. “We are excited to be able to add software like Visiopharm’s Phenomap to our current portfolio and offer Akoya customers the best and broadest solutions in the field of multiplexed immunofluorescence and tissue analysis.”

    The partnership with Akoya will cover both North America and Europe and support our joint vision of providing customers with a full suite of powerful image analysis solutions for high-dimensional, multiplex tissue assays.

    Visiopharm will present Phenomap, AI, and our infinitely configurable suite of image analysis software at Pathology Vision’s (booth #214) in San Diego on November 5th and 6th and at Society of Immunotherapy in Cancer (booth #223) on November 8th – 11th in Washington DC.

  • Deep Learning Methods Powered by AI in Tissue Image Analysis

    CIO Applications recently sat down with our founder and CEO Michael Grunkin. The technology print magazine focuses on usage of various tech s

    From tedious manual annotation work to fully automated annotations with a streamlined image analysis workflow. This is now possible with AI tools that are remarkably accurate generating powerful results within tissue segmentation, cell identification, quantification and other cell-based tasks.


    AI expands the possibilities in cancer research and diagnostics


    Whether you are looking for nuclei quantification in IHC images, accurate tumor separation in H&E, or advanced context aware region mapping in brain images, Oncotopix®/Biotopix™ AI image analysis is your go-to toolbox. Deep neural networks bring virtually endless possibilities to augmented pathology.

    AI made easy

    The Oncotopix®/Biotopix™ AI platform is train-by-example image analysis for digital pathology, made easy-to-use. Deep learning convolutional neural algorithms are trained based on easily annotated training data provided by you as the user. AI is not magic – you are in control of the learned behavior.

    Patented virtual double stain (VDS)

    Are you already using Artificial Intelligence (AI) for image analysis in digital pathology, and have you experienced the time-consuming task of annotating enough training data to capture the variance in your images? Let Visiopharm introduce you to our unique patented Virtual Double Stain (VDS) method for automatic annotation of training data.

    AI redefines what is possible in image analysis

    In more advanced cases robust identification of morphologically and/or functionally distinct features in histological samples, such as glomeruli in the kidney, compartments of the brain, and tumor/stroma separation, continues to challenge traditional image analysis methods. Differences in disease severity; preanalytical variables, such as variance in staining intensity; and structures or regions reliant solely on context often result in tedious manual annotations to achieve necessary accuracy.

    Stefan Hamann, PhD from the Translational Pathology Laboratory at Biogen has utilized Visiopharm’s context-based deep learning algorithms to automate the laborious manual tissue annotation process. The task involved sagittal mouse brain sections with 6 regions-of-interest. The result is a fully automated mouse brain annotation tool that is remarkably accurate when confronted with unique tissue artifacts, illuminating the possibilities of deep learning within a streamlined image analysis workflow.

    Visiopharm’s AI webinar

    Watch our webinar to experience Oncotopix®/Biotopix™ AI image analysis with real-life applications, where Visiopharm’s deep learning experts demonstrate the “how to” with explanations and relevant demo cases.

    Visiopharm AI image analysis solution


    The Oncotopix® and Biotopix™ AI image analysis modules are available and fully integrated with the Visiopharm current image analysis software platform. Visit visiopharm.com/ai-deeplearning

    Visiopharm AI Image Analysis in the news

    Please see the launch news at TissuePathology: Keith Kaplans Digital Pathology Blog

  • Visiopharm & Fuidigm Co-promote Phenomap Image Analysis Software & Hyperion Imaging System

    Fluidigm Announces Co-Marketing Agreement with Visiopharm to Expand and Simplify Imaging Mass Cytometry Data Analysis

    Visiopharm Multiplex software presented at the Fluidigm Imaging Mass Cytometry User Group Meeting, expanding the suite of Hyperion Imaging System data analysis tools for translational and clinical research 

    Fluidigm Corporation (NASDAQ:FLDM) and Visiopharm A/S today announced a co-marketing relationship to automate image analysis for Imaging Mass Cytometry™ (IMC™). Under the terms of this agreement, Fluidigm and Visiopharm will cooperatively promote Visiopharm® image analysis software in conjunction with the Fluidigm® Hyperion™ Imaging System, MCD™ Viewer software and related Maxpar® antibodies and kits.

    Developed using proven Fluidigm CyTOF® technology, the Hyperion Imaging System surpasses the inherent limitations of fluorescence detection by using highly pure metal tags that are separated by mass instead of by wavelength. Setting a new standard in highly multiplexed protein detection, the system enables researchers to simultaneously detect up to 37 markers from a single tissue section by IMC. Providing comprehensive analysis of cellular phenotypes and their interrelationships within the spatial context of the tissue microenvironment, IMC is aiding researchers around the world to uncover meaningful new insights in health and disease.

    “We are committed to maximizing the full potential of mass cytometry to deeply interrogate tissue and tumor samples,” said Chris Linthwaite, President and CEO of Fluidigm. “Today we are excited to announce our agreement with Visiopharm, a leader in quantitative digital pathology software solutions. Together with Visiopharm, we are proud to bring new software capabilities to our growing IMC community.”

    On September 11, Visiopharm will present its Multiplex software at the Fluidigm Imaging Mass Cytometry User Group Meeting in Seattle. Developed as an expansion of the Oncotopix® Discovery platform, Multiplex enables researchers to perform automated analysis of images generated by the Hyperion Imaging System. Offered as a licensed software solution from Visiopharm, Multiplex provides automated cell segmentation and phenotyping of cell classes in addition to powerful visualization of cell populations with phenotypic charting and t-SNE clustering.

    “The collaboration between Fluidigm and Visiopharm will provide scientists novel tools to understand the biology of cancer, including the phenotyping of cells within the tumor microenvironment,” said Michael Grunkin, CEO of Visiopharm. “Our complementary technologies provide an entirely new research approach to drive drug-diagnostic co-development on a tissue-based platform, with the potential to also provide a new framework for precision medicine in cancer.”

    “Collaborating to provide high-value automated data analysis solutions for the Hyperion Imaging System is essential to our strategy to empower routine use of this powerful technology,” continued Linthwaite. “By introducing automation to the MCD™ Viewer analysis pipeline, Multiplex further expands the capabilities of the Hyperion Imaging System to advance our understanding of human disease and improve the future of care.”